Business Description
Champions Oncology Inc
NAICS : 325414
SIC : 2836
ISIN : US15870P3073
Total Employee Number:
306Description
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment which is oncology services. Its research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The company's pharmacology, biomarker, and data platforms are designed to facilitate drug discovery and development at lower costs and increased speeds. Its revenue is majorly derived from research services.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.08 | |||||
Equity-to-Asset | 0.15 | |||||
Debt-to-Equity | 1.15 | |||||
Debt-to-EBITDA | 13 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -0.2 | |||||
Beneish M-Score | -1.67 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 2.6 | |||||
3-Year EPS without NRI Growth Rate | 39.8 | |||||
3-Year Book Growth Rate | -6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 9.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.31 | |||||
9-Day RSI | 32.48 | |||||
14-Day RSI | 37.04 | |||||
3-1 Month Momentum % | 3.36 | |||||
6-1 Month Momentum % | -15.73 | |||||
12-1 Month Momentum % | -2.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.96 | |||||
Quick Ratio | 0.96 | |||||
Cash Ratio | 0.24 | |||||
Days Sales Outstanding | 38.03 | |||||
Days Payable | 65.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | 2.01 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 48 | |||||
Operating Margin % | -1.73 | |||||
Net Margin % | -1.87 | |||||
EBITDA Margin % | 0.58 | |||||
FCF Margin % | -8.47 | |||||
OCF Margin % | -7.53 | |||||
ROE % | -28.29 | |||||
ROA % | -3.75 | |||||
ROIC % | -4.54 | |||||
3-Year ROIIC % | -31.71 | |||||
ROC (Joel Greenblatt) % | -12.35 | |||||
ROCE % | -13.14 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 57.5 | |||||
PS Ratio | 1.35 | |||||
PB Ratio | 20.57 | |||||
Price-to-Tangible-Book | 22.15 | |||||
EV-to-EBIT | -77.47 | |||||
EV-to-EBITDA | 229.95 | |||||
EV-to-Forward-EBITDA | 29.66 | |||||
EV-to-Revenue | 1.34 | |||||
EV-to-Forward-Revenue | 1.24 | |||||
EV-to-FCF | -15.84 | |||||
Price-to-GF-Value | 0.85 | |||||
Price-to-Median-PS-Value | 0.6 | |||||
Earnings Yield (Greenblatt) % | -1.29 | |||||
FCF Yield % | -6.29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CSBR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Champions Oncology Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 59.424 | ||
| EPS (TTM) ($) | -0.08 | ||
| Beta | 0.2042 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.38 | ||
| Volatility % | 28.67 | ||
| 14-Day RSI | 37.04 | ||
| 14-Day ATR ($) | 0.340945 | ||
| 20-Day SMA ($) | 5.839305 | ||
| 12-1 Month Momentum % | -2.53 | ||
| 52-Week Range ($) | 5.215 - 8.74 | ||
| Shares Outstanding (Mil) | 13.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Champions Oncology Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Champions Oncology Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-12-15 16:30 | In 135 days | ||
| Second quarter earnings results for 2027 | 2026-12-15 | In 134 days | ||
| General meeting for 2026 | 2026-10-16 09:00 | In 75 days | ||
| First quarter earnings conference call for 2027 | 2026-09-15 16:30 | In 44 days | ||
| First quarter earnings results for 2027 | 2026-09-15 | In 43 days | ||
| Annual report for 2026 | 2026-07-30 | 5.46 (+1.38%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-07-27 16:30 | 6.13 (+2.17%) | ||
| Fourth quarter earnings results for 2026 | 2026-07-27 | 6.13 (+2.17%) | ||
| Third quarter earnings conference call for 2026 | 2026-03-12 16:30 | 5.90 (+1.90%) | ||
| Third quarter earnings results for 2026 | 2026-03-12 | 5.90 (+1.90%) |
Show
Entries
Champions Oncology Inc Frequently Asked Questions
What is Champions Oncology Inc(CSBR)'s stock price today?
The current price of CSBR is $5.76. The 52 week high of CSBR is $8.74 and 52 week low is $5.22.
When is next earnings date of Champions Oncology Inc(CSBR)?
The next earnings date of Champions Oncology Inc(CSBR) is 2026-09-15 Est..
Does Champions Oncology Inc(CSBR) pay dividends? If so, how much?
Champions Oncology Inc(CSBR) does not pay dividend.
Guru Commentaries on NAS:CSBR
No articles.
Press Release
Articles on Champions Oncology Inc
Is Champions Oncology Inc (CSBR) Undervalued After Q4 Loss? GF Score: 64/100, Revenue of $13.8M Misses Estimates
Jul 27, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers